The purpose of this study is to determine the safety, tolerability and maximum tolerated dose
of selinexor (KPT-330) in combination with Irinotecan in patients with solid tumors. A
secondary purpose is to evaluate the pharmacokinetics (PK) of selinexor with irinotecan.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Martin Gutierrez
Collaborators:
Hackensack Meridian Health Karyopharm Therapeutics Inc